BridgeMD
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC
EU CTIS ID: 2025-520792-67-00
What this study is testing
To evaluate the efficacy of shorter duration of standard of care treatment ([chemo]immunotherapy) for patients with metastatic NSCLC
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Advanced, metastatic non-small cell lung cancer UICC stage IV
- Having received first line immunotherapy or first line (chemo)immunotherapy for 6 months ±2 weeks
- Response or stable disease according to RECIST 1.1 as determined by imaging no older than 3 weeks at moment of randomization
- Signed and dated informed consent.
- ECOG PS 0-2 and fit and willing to continue treatment with first line (chemo-)immunotherapy as deemed by the treating physician
You likely can't join if
- Other systemic anti-cancer treatment for the disease under study other than the first line (chemo-)immunotherapy
- Any contra-indication (as per label) for treatment with immune checkpoint inhibitors
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.